Black Diamond Ownership

BDTX Stock  USD 1.69  0.01  0.60%   
Black Diamond holds a total of 56.66 Million outstanding shares. The majority of Black Diamond Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Black Diamond Therap to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Black Diamond. Please pay attention to any change in the institutional holdings of Black Diamond Therapeutics as this could imply that something significant has changed or is about to change at the company. Also note that nearly one hundred thirteen thousand three hundred twenty-four invesors are currently shorting Black Diamond expressing very little confidence in its future performance.
 
Shares in Circulation  
First Issued
2019-03-31
Previous Quarter
57 M
Current Value
55 M
Avarage Shares Outstanding
33.8 M
Quarterly Volatility
16.6 M
 
Covid
Some institutional investors establish a significant position in stocks such as Black Diamond in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Black Diamond, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Black Diamond Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Black Stock Ownership Analysis

About 98.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.14. Some equities with similar Price to Book (P/B) outperform the market in the long run. Black Diamond Therap recorded a loss per share of 1.27. The entity had not issued any dividends in recent years. Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Black Diamond operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 86 people. For more info on Black Diamond Therapeutics please contact the company at 617 252 0848 or go to https://www.blackdiamondtherapeutics.com.

Black Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Black Diamond is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Black Diamond Therapeutics backward and forwards among themselves. Black Diamond's institutional investor refers to the entity that pools money to purchase Black Diamond's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Dimensional Fund Advisors, Inc.2024-12-31
661.4 K
Affinity Asset Advisors, Llc2024-12-31
559.2 K
Millennium Management Llc2024-12-31
558.1 K
Boxer Capital Management, Llc2024-12-31
506 K
Boxer Capital Llc2024-09-30
506 K
Goldman Sachs Group Inc2024-12-31
483.8 K
Kennedy Capital Management Inc2024-12-31
433.8 K
Northern Trust Corp2024-12-31
382.7 K
Connor Clark & Lunn Inv Mgmt Ltd2024-12-31
246.7 K
T. Rowe Price Investment Management,inc.2024-12-31
10.5 M
Bellevue Group Ag2024-12-31
8.5 M
Note, although Black Diamond's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Black Diamond Therap Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Black Diamond insiders, such as employees or executives, is commonly permitted as long as it does not rely on Black Diamond's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Black Diamond insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Behbahani Ali over two weeks ago
Acquisition by Behbahani Ali of 1000000 shares of Black Diamond at 5.0 subject to Rule 16b-3
 
Hatzis-schoch Brent over a month ago
Acquisition by Hatzis-schoch Brent of 75000 shares of Black Diamond subject to Rule 16b-3
 
Campbell Shannon over three months ago
Acquisition by Campbell Shannon of 4500 shares of Black Diamond at 2.5 subject to Rule 16b-3
 
Hatzis-schoch Brent over three months ago
Acquisition by Hatzis-schoch Brent of 200000 shares of Black Diamond at 4.86 subject to Rule 16b-3
 
Raman Prakash over six months ago
Acquisition by Raman Prakash of 2694 shares of Black Diamond at 4.78 subject to Rule 16b-3
 
Erika Jones over six months ago
Acquisition by Erika Jones of 100000 shares of Black Diamond at 4.86 subject to Rule 16b-3
 
Raman Prakash over six months ago
Insider Trading
 
Versant Venture Capital Vi, L.p. over six months ago
Disposition of 221600 shares by Versant Venture Capital Vi, L.p. of Black Diamond at 6.3202 subject to Rule 16b-3
 
Yurasov Sergey over six months ago
Disposition of 250000 shares by Yurasov Sergey of Black Diamond at 1.79 subject to Rule 16b-3
 
Campbell Shannon over six months ago
Acquisition by Campbell Shannon of 2011 shares of Black Diamond at 4.98 subject to Rule 16b-3
 
Dhingra Kapil over six months ago
Acquisition by Dhingra Kapil of 30550 shares of Black Diamond at 4.65 subject to Rule 16b-3
 
Hatzis-schoch Brent over six months ago
Acquisition by Hatzis-schoch Brent of 200000 shares of Black Diamond at 2.92 subject to Rule 16b-3

Black Diamond Outstanding Bonds

Black Diamond issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Black Diamond Therap uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Black bonds can be classified according to their maturity, which is the date when Black Diamond Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Black Stock Analysis

When running Black Diamond's price analysis, check to measure Black Diamond's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Black Diamond is operating at the current time. Most of Black Diamond's value examination focuses on studying past and present price action to predict the probability of Black Diamond's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Black Diamond's price. Additionally, you may evaluate how the addition of Black Diamond to your portfolios can decrease your overall portfolio volatility.